AtaiBeckley Inc
ATAI
Company Profile
Business description
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
Contact
250 West 34th Street
New YorkNY10119
USAT: +1 332 282-0507
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
99
Stocks News & Analysis
stocks
Wide moat share expects luck to turn
A tough year for jackpots however earnings are expected to normalise.
stocks
ASX share’s growth story intact despite supply constraints
Short term supply challenges but Chinese growth story remains intact.
stocks
ASX healthcare giant rallies despite a fall in profits
Easing investor concerns and signalling a return to growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,269.70 | 13.70 | -0.15% |
| CAC 40 | 8,484.43 | 31.34 | 0.37% |
| DAX 40 | 26,136.56 | 153.52 | 0.59% |
| Dow JONES (US) | 53,277.01 | 517.80 | 0.98% |
| FTSE 100 | 10,816.56 | 68.40 | 0.64% |
| HKSE | 26,009.46 | 310.97 | 1.21% |
| NASDAQ | 26,180.46 | 113.29 | 0.43% |
| Nikkei 225 | 66,016.36 | 200.43 | -0.30% |
| NZX 50 Index | 13,972.66 | 52.84 | 0.38% |
| S&P 500 | 7,674.37 | 33.21 | 0.43% |
| S&P/ASX 200 | 9,058.90 | 6.90 | -0.08% |
| SSE Composite Index | 3,905.20 | 1.48 | 0.04% |